IP Library › Granted Patent US 12,139,536
Granted Patent B2
US 12,139,536 · App. 16/619,769 · Granted Nov 12, 2024

Guided combinational therapeutic antibody

Inventor: Guan Yongjun (Clarksville, MD)
C07K16/2827C07K16/32C07K2317/31C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,139,536
App. No.
16/619,769
Granted
Nov 12, 2024
Kind
B2
Abstract

The present invention relates to multi-specific antibodies comprising fine tuned combination of low affinity single binding domain fragments to selectively target double targets on cancer cell, and use thereof for therapy, such as for guided immunotherapy.

Claims (36)

1. An engineered bi-specific antibody, comprising:

(i) a first chain comprising a first antigen binding single domain linked to the N-terminal of CH1 of IgG heavy chain that binds a first target, and having a first affinity in a range between 10 −5 and 10 −8 M; and

(ii) a second chain comprising a second antigen binding single domain linked to the N-terminal of CL of light chain that binds a second target, and having a second affinity in a range between 10 −5 and 10 −8 M;

(iii) a third chain that is same as the first chain;

(iv) a fourth chain that is the same as the second chain;

wherein said first chain is linked to said second chain to form a first arm through dimerization between CH1 and CL, said third chain is linked to said fourth chain to form a second arm through dimerization between CH1 and CL,

wherein said first arm is identical to said second arm, and said first arm and said second arm is linked by the IgG Fc dimerization,

wherein said first target and second target are both co-localized on a target cell;

wherein said bi-specific antibody more specifically binds to said target cell than to cells only expressing either said first target or said second target, with an avidity in a range between 10 −9 and 10 −12 M;

wherein said affinity and avidity are measured by ELISA binding activity assay; and

wherein

(i) the heavy chain comprises any one of the sequences of SEQ ID No. 2, No. 4, No. 37, No. 41; and

(ii) the light chain comprises any one of the sequences of SEQ ID No. 6, No. 8, No. 39, No. 43, wherein said antibody binds to Her2 and CD47 double positive target cell; or

wherein

(iii) the heavy chain comprises any one of the sequences of SEQ ID No. 6, No. 8, No. 29, No. 33; and

(iv) the light chain comprises any one of the sequences of SEQ ID No. 10, No. 12, No. 31, No. 35, wherein said antibody binds to PD-L1 and CD47 double positive target cell.

2. The antibody of claim 1 , wherein said first target and second target is selected from the group consisting of a tumor target, a disease-specific receptor, and an immune regulatory function target.

3. The antibody of claim 2 , wherein said tumor target is Her2.

4. The antibody of claim 2 , wherein said immune regulatory function target is PD-L1 or CD47.

5. An engineered tri-specific antibody, comprising:

(i) a first chain comprising a first antigen binding single domain linked to the N-terminal of CH1 of IgG heavy chain that binds a first target, and having a first affinity in a range between 10 −5 and 10 −8 M; and

(ii) a second chain comprising a second antigen binding single domain linked to the N-terminal of CL of light chain that binds a second target, and having a second affinity in a range between 10 −5 and 10 −8 M;

(iii) a third chain that is same as the first chain;

(iv) a fourth chain that is the same as the second chain;

(v) a third antigen binding single domain linked to the C-terminal of CL of light chain that binds a third target, having a third affinity in a range between 10 −5 and 10 −8 M;

wherein said first chain is linked to said second chain to form a first arm through dimerization between CH1 and CL, said third chain is linked to said fourth chain to form a second arm through dimerization between CH1 and CL;

wherein said first arm is identical to said second arm, and said first arm and said second arm is linked by the IgG Fc dimerization;

wherein said first target and second target are both co-localized on a same target cell; and

wherein said tri-specific antibody more specifically bind to said target cell than to cells only expressing either said first target or said second target, with an avidity in a range between 10 −9 and 10 −12 M; and wherein said third target is an effector function target; wherein said third antigen binding domain mediates effector cells to the target cell; and

wherein said affinity and avidity are measured by ELISA binding activity assay,

wherein

i) the heavy chain comprises any one of the sequences of SEQ ID No. 2, No. 4, No. 37, No. 41; and

(ii) the light chain comprises any one of the sequences of SEQ ID No. 6, No. 8, No. 53, No. 55, No. 57, No. 59, wherein said antibody binds to Her2 and CD47 double positive target cell, or wherein

(iii) the heavy chain comprises any one of the sequences of SEQ ID No. 6, No. 8, No. 29, No. 33; and

(iv) the light chain comprises any one of the sequences of SEQ ID No. 10, No. 12, No. 45, No. 47, No. 49, No. 51, wherein said antibody binds to PD-L1 and CD47 double positive target cell.

6. The antibody of claim 5 , wherein said third target is selected from the group consisting of CD3, CD16a, and CD59.